08.07.15
Gilead
2Q Revenues: $8.2 billion (+26%)
2Q Earnings: $4.5 billion (+23%)
FY Revenues: $15.8 billion (+37%)
FY Earnings: $8.8 billion (+50%)
Comments: Antiviral product sales increased to $7.6 billion in the quarter, up 27% driven by Hep C drug Harvoni(with sales of $3.6 billion in the quarter and $7.2 billion YTD), which was approved in the U.S. and Europe in 4Q14, partially offset by a decrease in sales of Sovaldi (down 63% to $1.3 billion) due primarily to the uptake in Harvoni. Other product sales, which include Letairis(ambrisentan), Ranexa (ranolazine) and AmBisome(amphotericin B liposome for injection), were $495 million in the quarter compared to $401 million
2Q Revenues: $8.2 billion (+26%)
2Q Earnings: $4.5 billion (+23%)
FY Revenues: $15.8 billion (+37%)
FY Earnings: $8.8 billion (+50%)
Comments: Antiviral product sales increased to $7.6 billion in the quarter, up 27% driven by Hep C drug Harvoni(with sales of $3.6 billion in the quarter and $7.2 billion YTD), which was approved in the U.S. and Europe in 4Q14, partially offset by a decrease in sales of Sovaldi (down 63% to $1.3 billion) due primarily to the uptake in Harvoni. Other product sales, which include Letairis(ambrisentan), Ranexa (ranolazine) and AmBisome(amphotericin B liposome for injection), were $495 million in the quarter compared to $401 million